Clinical and Administrative Data on the Research of Acute Coronary Syndrome in Spain. Minimum Basic Data Set Validity

Bernal, José Luís; Barrabés, José A.; Íñiguez, Andrés; Fernández‐Ortíz, Antonio; Fernández-Pérez, Cristina; Bardajı́, Alfredo; Elola, Francisco Javier

doi:10.1016/j.rec.2018.01.026

Cited by 18 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, we used hospital discharge records (the CMBD database) to identify CVD and other diagnoses. This data source has proven to be a useful tool to provide quality information in the field of CVD [ 30 , 31 ]. Third, our analysis was limited to incident users of lipid-lowering treatment, thereby diminishing differences between our results and those of randomized clinical trials [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

Aguilar-Palacio

Rabanaque

Maldonado

et al. 2020

IJERPH

View full text Add to dashboard Cite

The objective of this study was to analyse persistence to lipid-lowering drug use for primary prevention of cardiovascular disease (CVD) in a new users cohort, to explore all-cause and cardiovascular related morbidity, comorbidity and mortality in this group and, finally, to study the relationship between persistence and morbimortality. We selected subjects who started lipid-lowering treatment for primary prevention of CVD between 1 January 2010 and 31 December 2017 (N = 1424), and classified them as treatment-persistent or -nonpersistent. Bivariate analyses were performed to compare sociodemographic and clinical variables, morbimortality and time to event between groups. The association between morbidities was explored using comorbidity network analysis. The effect of persistence was analysed using logistic regression and Cox survival analyses. Only 38.7% of users were persistent with treatment. Persistent and nonpersistent users had similar sociodemographic and clinical profiles, although differed in age, smoking status, and glycemia. Comorbidity networks revealed that the number of co-occurring diagnoses was higher in nonpersistent than persistent users. Adjusted analyses indicated a protective effect of treatment persistence, especially against major adverse cardiovascular events (MACE), but this effect was not statistically significant. Observational studies are crucial to characterize real-world effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

Aguilar-Palacio

Rabanaque

Maldonado

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…One study validated I21-I22 (PPV 89%) 47 and another I21-I24 (PPV 75%). 32 The estimates for ICD-10 codes were no higher than those for ICD-8 (PPV 79-100%), 26,27,80,84,88 ICD-9 (86-100%), 42,50,58,65,75,98 or combinations of three ICD systems (PPV 82-96%). 37,87 Of the studies to validate data in primary care, one 23 included IPCI K75 code (PPV 75%) and three 50,52,53 validated Read coding in the UK (PPV 91-93%).…”

Section: Coding Systemmentioning

confidence: 93%

“…Similar to HF, ACS diagnoses were most frequently validated using EHR data from Denmark (nine studies),- 22,23,26,27,29,30,32,34,37 followed by Finland (seven studies), [68][69][70]81,84,99,100 the UK (six studies) 42,46,47,50,52,53 and Sweden (4 studies). 58,80,87,88 Two studies validated data in each of Italy, 23,75 the Netherlands, 23,65 and Spain, 91,98 and a final study used data from France. 76 Twenty-six of the studies validated a secondary care EHR, 22,26,27,29,30,32,34,37,42,47,58,65,[68][69][70]75,76,…”

Section: Acute Coronary Syndrome Study Characteristicsmentioning

confidence: 99%

“…58,80,87,88 Two studies validated data in each of Italy, 23,75 the Netherlands, 23,65 and Spain, 91,98 and a final study used data from France. 76 Twenty-six of the studies validated a secondary care EHR, 22,26,27,29,30,32,34,37,42,47,58,65,[68][69][70]75,76,80,81,84,87,88,91,[98][99][100] three studies validated both a primary and secondary care EHR 23,50,53 and two studies validated a primary care EHR. 46,52 Four studies 22,37,68,76 presented overall ACS results, of which one study 68 included an additional breakdown for MI and two studies 37,76 included unstable angina and M...…”

Section: Acute Coronary Syndrome Study Characteristicsmentioning

confidence: 99%

“…Sensitivity was only reported by one study, 65 at 53%. For MI, the main validation result for sensitivity (11 studies) 26,27,34,42,46,50,58,65,81,88,98 was ≥80% in…”

Section: Diagnosis Typementioning

confidence: 99%

See 2 more Smart Citations

<p>Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review</p>

Davidson¹,

Banerjee²,

Muzambi³

et al. 2020

CLEP

View full text Add to dashboard Cite

Background: Electronic health records are widely used in cardiovascular disease research. We appraised the validity of stroke, acute coronary syndrome and heart failure diagnoses in studies conducted using European electronic health records. Methods: Using a prespecified strategy, we systematically searched seven databases from dates of inception to April 2019. Two reviewers independently completed study selection, followed by partial parallel data extraction and risk of bias assessment. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value estimates were narratively synthesized and heterogeneity between sensitivity and PPV estimates were assessed using I 2. Results: We identified 81 studies, of which 20 validated heart failure diagnoses, 31 validated acute coronary syndrome diagnoses with 29 specifically recording estimates for myocardial infarction, and 41 validated stroke diagnoses. Few studies reported specificity or negative predictive value estimates. Sensitivity was ≤66% in all but one heart failure study, ≥80% for 91% of myocardial infarction studies, and ≥70% for 73% of stroke studies. PPV was ≥80% in 74% of heart failure, 88% of myocardial infarction, and 70% of stroke studies. PPV by stroke subtype was variable, at ≥80% for 80% of ischaemic stroke but only 44% of haemorrhagic stroke. There was considerable heterogeneity (I 2 >75%) between sensitivity and PPV estimates for all diagnoses. Conclusion: Overall, European electronic health record stroke, acute coronary syndrome and heart failure diagnoses are accurate for use in research, although validity estimates for heart failure and individual stroke subtypes were lower. Where possible, researchers should validate data before use or carefully interpret the results of previous validation studies for their own study purposes.

show abstract

One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018

et al. 2023

View full text Add to dashboard Cite

Clinical and Administrative Data on the Research of Acute Coronary Syndrome in Spain. Minimum Basic Data Set Validity

Cited by 18 publications

References 39 publications

New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study

<p>Validity of Acute Cardiovascular Outcome Diagnoses Recorded in European Electronic Health Records: A Systematic Review</p>

One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018

Contact Info

Product

Resources

About